Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients

Wiener Klinische Wochenschrift

Volumn 116, Issue 21-22, 2004, Pages 755-759

  Tomažič, Janez ^a   Silič, Anja ^b   Karner, Primož ^a   Vidmar, Ludvik ^a   Matičič, Mojca ^a   Poljak, Mario ^b   Ihan, Alojz ^b   Janež, Andrej ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Dyslipidemia; Glucose metabolism; Highly active antiretroviral therapy; HIV; Lipodystrophy

Indexed keywords

ABACAVIR; AMPRENAVIR; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; GLUCOSE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DEPENDENCE; DRUG DOSE REGIMEN; DYSLIPIDEMIA; EVALUATION; FEMALE; FREQUENCY ANALYSIS; HEALTH SURVEY; HEMOPHILIA; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPID STORAGE; LIPOATROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBSERVATION; PREVALENCE; SEXUAL INTERCOURSE; SLOVENIA; T LYMPHOCYTE; VIRUS TRANSMISSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; GLUCOSE INTOLERANCE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MALE; MIDDLE AGED; SLOVENIA;

EID: 10644220427     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-004-0268-9     Document Type: Article

References (33)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860
2. The CASCADE Collaboration (2000) Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 355: 1158-1159
3. Aliyu MH, Salihu HM (2003) Tuberculosis and HIV disease: two decades of a dual epidemic. Wien Klin Wochenschr 115: 685-697
4. Behrens GMN, Meyer-Olson D, Stoll M, Schmidt RE (2003) Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 17 [Suppl 1]: S149-S154
5. Carr A, Samaras K, Burton S, et al (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58
6. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA (1999) Diagnosis, prediction and natural course of HIV-1 protease inhibitor associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 353: 2093-2099
7. Nolan D, Mallal S (2001) Getting to the HAART of insulin resistance. AIDS 15: 2037-2041
8. Bodasing N, Fox R (2003) HIV-accociated lipodystrophy syndrome: assessment and management. J Infect 46: 87-93
9. Fantoni M, Del Borgo C, Autore C (2003) Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 17 [Suppl 1]: S162-S169
10. Mulligan K, Grunfeld C, Tai VW (2000) Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 23: 35-43
11. Bodasing N, Fox R (2003) HIV-associated lipodystrophy syndrome: description and pathogenesis. J Infect 46: 149-154
12. Moyle GJ, Datta D, Mandalia S, et al (2002) Hyperlactatemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 16: 1341-1349
13. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17: 1917-1923
14. Koch RO, Graziadei IW, Zangerle R, Romani N, Maier H, Vogel W (2003) Hepatic failure and lactate acidosis associated with antiretroviral treatment for HIV. Wien Klin Wochenschr 115: 135-140
15. Carr A, Miller J, Law M, Cooper DA (2000) A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14: F25-F32
16. Périard D, Telenti A, Sudre P, et al (1999) Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 100: 700-705
17. Braitstein P, Yip B, Heath KV, at al (2003) Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995-2000. AIDS 17: 2071-2075
18. Mooser V (2003) Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease. AIDS 17 [Suppl 1]: S65-S69
19. Vittecoq D, Escaut L, Chironi G, et al (2003) Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 17 [Suppl 1]: S70-S76
20. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database (2003) Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17: 2479-2486
21. Lipshultz SE, Fisher SD, Lai WW, Miller TL (2003) Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 17 [Suppl 1]: S96-S122
22. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Infect 348: 702-710
23. Klein D, Hurley LB, Sidney S (2003) Cardiovascular disease and HIV infection. N Engl J Infect 349: 1869-1870
24. Friis- Moeller N, Weber R, Reiss P, et al (2003) Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 17: 1179-1193
25. Carr A (2003) HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17 [Suppl 1]: S141-S148
26. Saves M, Raffi F, Capeau J, et al (2002) Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 34: 1396-1405
27. Martinez E, Mocroft A, Garcia-Viejo MA, et al (2001) Risk of lipodystrophy in HIV-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357: 592-598
28. Bogner JR, Vielhauer V, Beckmann RA, et al (2001) Stavudine versus zidovudine and the development of lipodystrophy. J AIDS 27: 237-244
29. Carr A, Emerly S, Law M, Puls R, Lundgren JD, Powderly WG (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361: 726-735
30. Boix V (2003) Polylactic acid implants. A new smile for lipoatrophic faces? AIDS 17: 2533-2535
31. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN (1989) Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 86: 27-31
32. Bonnet F, Savès M, Droz C, et al (2000) Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens [letter]. J Acquir Immune Defic Syndr 25: 199-200
33. Shikuma CM, Waslien C, McKeague J, et al (1999) Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS. AIDS 13: 1359-1365